Two new drugs used for preventing blood clot formation could result in improved outcomes in the treatment for heart diseases.
According to the researchers, the drug can reduce rate of repeat heart attacks, as compared to bivalirudin which is more expensive.
The results of the HEAT-PPCI trial suggest that systematic use of heparin rather than bivalirudin after primary percutaneous coronary intervention (PPCI) - the most commonly used treatment for heart attack, which unblocks the arteries carrying blood to the heart - could save health services substantial sums of money, at the same time as potentially improving patient outcomes.
Dr Rod Stables, lead author said that their study is one of the first trials to recruit 100 percent of eligible patients presenting with the medical condition being examined, which means that it more closely resembles real life practice than many previous trials and added that his finding might provide an opportunity, rare in modern health care, to provide improved outcomes at much reduced cost.
The study was published in The Lancet.